Piceatannol

Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)^[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties^[2]. Piceatannol induces apoptosis in DLBCL cell lines^[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells^[4]. In Vitro: Piceatannol is a resveratrol metabolite^[2].
SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25, and 50 μM; 72 hours) inhibits cell growth of six diffuse large B cell lymphomas (DLBCL) cell lines (SUDHL-6, U2392,DOHH2,Karpas 422, VAL, OCI Ly19) with IC₅₀s of 18 μM, 25 μM, 37 μM, 48 μM, >50 μM and >50 μM, respectively^[3]. In Vivo: Piceatannol (10, 20, and 40 mg/kg) inhibits the pulmonary edema and reduces the infiltration of inflammatory cells induced by lipopolysaccharide^[1].
Piceatannol (10, 20, and 40 mg/kg) alleviates the myeloperoxidase activity and inhibits the production of iNOS and COX-2 expressions in lung tissuesinduced by lipopolysaccharide^[1].
Piceatannol (10, 20, and 40 mg/kg; intraperitoneally 1 h) treatment alleviates inflammatory response by inhibiting the activation of TLR/NF-κB signaling pathway in lung tissues during acute lung injury (ALI) induced by LPS^[1].